Astellas Pharma (OTCMKTS:ALPMY) Sets New 1-Year High – Time to Buy?

Astellas Pharma Inc. (OTCMKTS:ALPMY)’s share price hit a new 52-week high on Monday . The company traded as high as $17.35 and last traded at $16.30, with a volume of 2014 shares changing hands. The stock had previously closed at $15.78.

Analyst Upgrades and Downgrades

A number of research firms recently commented on ALPMY. Citigroup downgraded Astellas Pharma from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 19th. Smbc Nikko Sec. raised Astellas Pharma to a “hold” rating in a research note on Monday, February 16th. Finally, Jefferies Financial Group upgraded Astellas Pharma from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, March 24th. One investment analyst has rated the stock with a Strong Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold”.

Astellas Pharma Trading Up 1.1%

The company’s 50 day moving average price is $15.28 and its two-hundred day moving average price is $13.23. The firm has a market cap of $29.43 billion, a PE ratio of 13.66 and a beta of 0.15. The company has a quick ratio of 0.84, a current ratio of 1.09 and a debt-to-equity ratio of 0.23.

Astellas Pharma (OTCMKTS:ALPMY) last issued its quarterly earnings results on Wednesday, February 4th. The company reported $0.44 EPS for the quarter, beating the consensus estimate of $0.29 by $0.15. The company had revenue of $3.67 billion for the quarter, compared to the consensus estimate of $3.21 billion. Astellas Pharma had a net margin of 15.63% and a return on equity of 23.62%. As a group, sell-side analysts forecast that Astellas Pharma Inc. will post 0.42 EPS for the current year.

Astellas Pharma Company Profile

Astellas Pharma Inc is a Tokyo-based, global pharmaceutical company traded in the United States as an American Depositary Receipt on the OTC Markets under the symbol ALPMY. The company focuses on discovering, developing and marketing prescription medicines in key therapeutic areas, including oncology, urology, immunology, neuroscience and cardiovascular/metabolic diseases. Astellas seeks to bring innovative treatments to market by combining internal research capabilities with external partnerships and collaborative agreements around the world.

Core products in Astellas’ portfolio include the immunosuppressant Prograf (tacrolimus), the overactive bladder treatments Vesicare (solifenacin) and Myrbetriq (mirabegron), and the prostate cancer therapy Xtandi (enzalutamide).